{"qas": [{"plausible_answers": [{"text": "if the risk of cardiovascular events is felt to be high and early PCI is being considered", "answer_start": 186}], "question": "When is clopidogrel removed?", "id": "5a6bb9624eec6b001a80a538", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "no ST elevation", "answer_start": 45}], "question": "What is NSTEACS an abbreviation for?", "id": "5a6bb9624eec6b001a80a539", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Xa", "answer_start": 329}], "question": "Clopidogrel is a form of what inhibitor?", "id": "5a6bb9624eec6b001a80a53a", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "inhibitors of the platelet glycoprotein \u03b1IIb\u03b23a receptor", "answer_start": 478}], "question": "What inhibitors are used in low-risk scenarios?", "id": "5a6bb9624eec6b001a80a53b", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "low", "answer_start": 392}], "question": "Eptifibatide has what kind of molecular weight?", "id": "5a6bb9624eec6b001a80a53c", "answers": [], "is_impossible": true}], "context": "People with an acute coronary syndrome where <b1_0>no ST elevation<b1_0/> is demonstrated (non-ST elevation ACS or NSTEACS) are treated with aspirin. Clopidogrel is added in many cases, particularly <b0_0>if the risk of cardiovascular events is felt to be high and early PCI is being considered<b0_0/>. Depending on whether early PCI is planned, a factor <b2_0>Xa<b2_0/> inhibitor or a potentiator of antithrombin (fondaparinux or <b4_0>low<b4_0/> molecular weight heparin respectively) may be added. In very high-risk scenarios, <b3_0>inhibitors of the platelet glycoprotein \u03b1IIb\u03b23a receptor<b3_0/> such as eptifibatide or tirofiban may be used."}